Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impaired intestinal permeability in patients with multiple sclerosis

L. Fialova, P. Barilly, I. Stetkarova, A. Bartos, L. Noskova, D. Zimova, M. Zido, I. Hoffmanova

. 2025 ; 169 (1) : 37-43. [pub] 20230811

Language English Country Czech Republic

Document type Journal Article

BACKGROUND: A number of recent studies have shown that the intestinal microbiome, part of the brain-gut axis, is implicated in the pathophysiology of multiple sclerosis. An essential part of this axis, is the intestinal barrier and gastrointestinal disorders with intestinal barrier dysregulation appear to be linked to CNS demyelination, and hence involved in the etiopathogenesis of multiple sclerosis (MS). OBJECTIVE: The aim of this study was to evaluate the integrity of the intestinal barrier in patients with clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) using two serum biomarkers, claudin-3 (CLDN3), a component of tight epithelial junctions, and intestinal fatty acid binding protein (I-FABP), a cytosolic protein in enterocytes. METHODS: Serum levels of CLDN3 in 37 MS patients and 22 controls, and serum levels of I-FABP in 46 MS patients and 51 controls were measured using commercial ELISA kits. Complete laboratory tests excluded the presence of gluten-related disorders in all subjects. Thirty MS patients received either disease-modifying drugs (DMD), immunosuppression (IS) or corticosteroid treatment. RESULTS: CLDN3 levels were only significantly higher in the MS patients treated with DMD or IS compared to the control group (P=0.006). There were no differences in I-FABP serum levels between the groups. Serum CLDN3 levels did not correlate with serum I-FABP levels in CDMS, in CIS patients or controls. CONCLUSIONS: In multiple sclerosis patients, the intestinal epithelium may be impaired with increased permeability, but without significant enterocyte damage characterized by intracellular protein leakage. Based on our data, CLDN3 serum levels appear to assess intestinal dysfunction in MS patients but mainly in treated ones.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008986
003      
CZ-PrNML
005      
20250522101940.0
007      
ta
008      
250411s2025 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.033 $2 doi
035    __
$a (PubMed)37581230
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Fialová, Lenka, $d 1957- $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0074272
245    10
$a Impaired intestinal permeability in patients with multiple sclerosis / $c L. Fialova, P. Barilly, I. Stetkarova, A. Bartos, L. Noskova, D. Zimova, M. Zido, I. Hoffmanova
520    9_
$a BACKGROUND: A number of recent studies have shown that the intestinal microbiome, part of the brain-gut axis, is implicated in the pathophysiology of multiple sclerosis. An essential part of this axis, is the intestinal barrier and gastrointestinal disorders with intestinal barrier dysregulation appear to be linked to CNS demyelination, and hence involved in the etiopathogenesis of multiple sclerosis (MS). OBJECTIVE: The aim of this study was to evaluate the integrity of the intestinal barrier in patients with clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) using two serum biomarkers, claudin-3 (CLDN3), a component of tight epithelial junctions, and intestinal fatty acid binding protein (I-FABP), a cytosolic protein in enterocytes. METHODS: Serum levels of CLDN3 in 37 MS patients and 22 controls, and serum levels of I-FABP in 46 MS patients and 51 controls were measured using commercial ELISA kits. Complete laboratory tests excluded the presence of gluten-related disorders in all subjects. Thirty MS patients received either disease-modifying drugs (DMD), immunosuppression (IS) or corticosteroid treatment. RESULTS: CLDN3 levels were only significantly higher in the MS patients treated with DMD or IS compared to the control group (P=0.006). There were no differences in I-FABP serum levels between the groups. Serum CLDN3 levels did not correlate with serum I-FABP levels in CDMS, in CIS patients or controls. CONCLUSIONS: In multiple sclerosis patients, the intestinal epithelium may be impaired with increased permeability, but without significant enterocyte damage characterized by intracellular protein leakage. Based on our data, CLDN3 serum levels appear to assess intestinal dysfunction in MS patients but mainly in treated ones.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a claudin-3 $x metabolismus $7 D062465
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    12
$a roztroušená skleróza $x patofyziologie $x metabolismus $x krev $7 D009103
650    _2
$a lidé středního věku $7 D008875
650    12
$a permeabilita $7 D010539
650    12
$a proteiny vázající mastné kyseliny $x krev $7 D050556
650    12
$a biologické markery $x krev $7 D015415
650    _2
$a střevní sliznice $x metabolismus $7 D007413
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a funkce střevní bariéry $7 D000095644
655    _2
$a časopisecké články $7 D016428
700    1_
$a Barilly, Pavla, $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $d 1987- $7 xx0332491
700    1_
$a Štětkářová, Ivana, $d 1963- $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0030376
700    1_
$a Bartoš, Aleš $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0028753
700    1_
$a Nosková, Libuše $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0224705
700    1_
$a Zimová, Denisa $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0240113
700    1_
$a Židó, Michal $u Department of Neurology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0269356
700    1_
$a Hoffmanová, Iva $u Department of Internal Medicine, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $7 xx0101007
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 169, č. 1 (2025), s. 37-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37581230 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20250411 $b ABA008
991    __
$a 20250522101936 $b ABA008
999    __
$a ok $b bmc $g 2324862 $s 1246064
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 169 $c 1 $d 37-43 $e 20230811 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20250411

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...